

Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with moderately to severely active ulcerative colitis

Laurent Peyrin-Biroulet,¹ Julián Panés,² Michael Chiorean,³ Jinkun Zhang,⁴ Séverine Vermeire,⁵ Vipul Jairath,⁶ Andres Yarur,⁷ Chris Cabell,⁴ Snehal Naik,⁴ William J. Sandborn⁸

¹University Hospital of Nancy, Vandœuvre-lès-Nancy, France; ²Hospital Clinic of Barcelona, DIBAPS, CIBERehd, Barcelona, Spain; ³Virginia Mason Medical Center, Seattle, WA, USA; ⁴Arena Pharmaceuticals, Inc., San Diego, CA, USA; ⁵University Hospitals Leuven, Leuven, Flanders, Belgium; ⁶Western University, London, Ontario, Canada; ⁷Medical College of Wisconsin, Milwaukee, WI, USA; ⁸University of California San Diego, La Jolla, CA, USA

Background: Etrasimod (APD334), an oral, selective sphingosine-1-phosphate receptor modulator, was evaluated in the randomised, double-blind, placebo-controlled, parallel-group, phase 2 OASIS study (ClinicalTrials.gov identifier: NCT02447302) in patients with moderately to severely active ulcerative colitis (UC). Etrasimod demonstrated dose-dependent improvements in clinical response, clinical remission, and endoscopic appearance and decreased circulating lymphocytes. Here, we describe histological remission and mucosal healing results at week 12.

Methods: Patients were randomised to receive once-daily etrasimod 1 mg (n=52) or 2 mg (n=50), with no dose titration, or placebo (n=54). At baseline and week 12, endoscopic severity was assessed by sigmoidoscopy with central readings using the Mayo endoscopic subscore. Biopsies were taken, and histology results were scored by a blinded central pathologist using the Geboes index. Prespecified endpoint definitions were endoscopic improvement (Mayo endoscopic subscore of 0 or 1); histological improvement (Geboes score <3.1); and histological remission (Geboes score <2.0). Mucosal healing (a post hoc analysis) was defined as both endoscopic improvement and histological remission. Differences between groups were estimated using the Mantel–Haenszel analysis adjusted for current corticosteroid use at baseline and prior anti-tumour necrosis factor alpha use.

Results: Of 156 patients randomised, 90% completed the study. Etrasimod 2 mg, compared with placebo, resulted in significantly more patients who achieved endoscopic improvement (43.2% vs 16.3%, respectively; $P=0.003$), histological improvement (31.7% vs 10.2%; $P=0.006$), and histological remission (19.5% vs 6.1%; $P=0.027$) at week 12 (Table). Mucosal healing was seen in 19.5% and 4.1% of patients treated with etrasimod 2 mg and placebo, respectively ($P=0.010$). More patients receiving etrasimod 1 mg also achieved each endpoint compared with placebo; however, results did not reach statistical significance.

Conclusion: Etrasimod 2 mg induced significantly higher rates of endoscopic improvement, histological improvement and remission, and mucosal healing in patients with moderately to severely active UC when compared with placebo. Mucosal healing may prove to be an achievable and objective measure of drug efficacy in UC induction studies.

Table. Endoscopic, Histological, and Mucosal Measures at Week 12

Efficacy Measure	Etrasimod 1 mg (n=49)	Etrasimod 2 mg (n=41)	Placebo (n=49)
Endoscopic improvement (Mayo endoscopic subscore ≤1)			
Patients achieving, %	22.0 ^a	43.2 ^b	16.3
Difference from placebo ^c (90% CI)	5.1 (-7.7 to 18.0) <i>P</i> =0.261	25.9 (11.0 to 40.8) <i>P</i> =0.003	
Histological improvement (Geboes score <3.1)			
Patients achieving, %	20.4	31.7	10.2
Difference from placebo ^c (90% CI)	9.9 (-1.8 to 21.7) <i>P</i> =0.090	21.2 (7.5 to 35.0) <i>P</i> =0.006	
Histological remission (Geboes score <2.0)			
Patients achieving, %	10.2	19.5	6.1
Difference from placebo ^c (90% CI)	3.4 (-5.7 to 12.5) <i>P</i> =0.271	13.3 (1.9 to 24.8) <i>P</i> =0.027	
Mucosal healing^d (Both endoscopic improvement and histological remission)			
Patients achieving, %	8.2	19.5	4.1
Difference from placebo ^c (90% CI)	3.6 (-4.3 to 11.5) <i>P</i> =0.231	15.4 (4.3 to 26.4) <i>P</i> =0.010	

CI, confidence interval. Modified intention-to-treat population. All *P* values are 1-sided.

^an=50; ^bn=44; ^cMantel–Haenszel estimate, adjusted for current corticosteroid use at baseline and prior anti-tumour necrosis factor alpha use; ^dPost hoc analysis.